| Identification | More | [Name]
Diaveridine | [CAS]
5355-16-8 | [Synonyms]
2,4-DIAMINO-5-(3,4-DIMETHOXY BENZYL)PYRIMIDINE
5-(3,4-DIMETHOXYBENZYL)-2,4-PYRIMIDINEDIAMINE
5-(3,4-DIMETHOXY-BENZYL)-PYRIMIDINE-2,4-DIAMINE
5-[(3,4-DIMETHOXYPHENYL)METHYL]-2,4-PYRIMIDINEDIAMINE
DIAVERIDIN
DIAVERIDINE
2,4-diamino-5-veratryl-pyrimidin
5-((3,4-dimethoxyphenyl)methyl)-4-pyrimidinediamine
diaveridinecrystalline
DVD
egis5645
DIVERDINE
2,4-Pyrimidinediamine, 5-(3,4-dimethoxyphenyl)methyl-
Diaveridin(DVD)
2,4-Diamino-5-veratrylpyrimidine
5-(3,4-Dimethoxybenzyl)-2,4-diaminopyrimidine
BW 49-210
NSC-408735 | [EINECS(EC#)]
226-333-3 | [Molecular Formula]
C13H16N4O2 | [MDL Number]
MFCD00057349 | [Molecular Weight]
260.29 | [MOL File]
5355-16-8.mol |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [WGK Germany ]
2
| [RTECS ]
UV8142000
| [HS Code ]
29335990 |
| Hazard Information | Back Directory | [Uses]
Antibacterial. | [Definition]
ChEBI: An aminopyrimidine in which the pyrimidine ring carries amino substituents at C-2 and C-4 and a 3,4-dimethoxybenzyl group at C-5. A folic acid antagonist, it is used as a synergist with sulfonamides against the parasitic Eimeria species. | [in vivo]
The sperm abnormality of the Diaveridine (DVD) treatment groups at all dose levels (Diaveridine, 128 to 512 mg/kg) shows no significant differences compare with the negative control group. There are no significant differences of micronucleus between the negative control group and the Diaveridine treatment groups (Diaveridine, 128 to 512 mg/kg). The chromosome aberration of the Diaveridine treatment groups at all dose levels and the negative control group are significantly lower than those in the positive control group treated with cyclophosphamide (P<0.05), indicating that Diaveridine at the doses studied does not cause abnormal chromosome aberration. The results demonstrate that the Diaveridine administration does not produce significant changes in the ratio of organ-to-body weight, compare with the negative control group in the end period of the study[3]. | [storage]
Store at -20°C |
|
|